Pfizer Partners With Protalix On Gaucher Drug Eyeing Lower Cost Plant-Based Production
Pfizer agrees to pay $60 million upfront for rights to taliglucerase, an investigational competitor to Genzyme's Cerezyme.
Pfizer agrees to pay $60 million upfront for rights to taliglucerase, an investigational competitor to Genzyme's Cerezyme.